Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma

“…In an effort to improve the response before performing an autologous hematopoietic stem cell transplantation, we discussed the second therapy line financed in Spain among the following: pomalidomide‐bortezomib‐dexamethasone (PVD), carfilzomib‐dexamethasone (KD), isatuximab‐pomalidomide‐dexamethasone (ISA‐PomaDexa), or isatuximab‐carfilzomib‐dexamethasone (ISA‐KD). The inclusion of the patient in a clinical trial (e.g., anti‐BCMA CAR‐T, a CD3xBCMA bispecific monoclonal antibody, or a venetoclax‐based combination) was also considered 16–19 …”

“…The inclusion of the patient in a clinical trial (e.g., anti‐BCMA CAR‐T, a CD3xBCMA bispecific monoclonal antibody, or a venetoclax‐based combination) was also considered. 16 , 17 , 18 , 19 …”

Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy

“…Until a few years ago, regimens for induction therapy commonly included a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and dexamethasone (a three-drug therapy-triplet). More recently, the introduction of anti-CD38 monoclonal antibodies, daratumumab and isatuximab, has changed the treatment paradigm for transplant-eligible NDMM patients in that quadruplets have supplanted triplets [14,15].…”